MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 04-28-2026
NeoGenomics Cost of Revenue 2011-2026 | NEO
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue NeoGenomics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 413 M | 370 M | 347 M | 322 M | 297 M | 259 M | 212 M | 149 M | 138 M | 134 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 413 M | 134 M | 264 M |
Quarterly Cost of Revenue NeoGenomics
| 2026-Q1 | 2025-Q4 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 106 M | - | 104 M | 94.8 M | - | 92.9 M | 92 M | 90.8 M | - | 89.6 M | 87 M | 82.4 M | - | 79.9 M | 81.1 M | 78.9 M | - | 74.1 M | 68.7 M | 74 M | - | 71.4 M | 59 M | 59.7 M | - | 53.8 M | 52.7 M | 48.5 M | - | 36.8 M | 37.2 M | 36.1 M | - | 34.2 M | 34.9 M | 34.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 106 M | 34.2 M | 68.7 M |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K |  USA |
 |
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | USA |
|
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
222 K | $ 5.63 | -2.26 % | $ 7.49 M | USA |
 |
Castle Biosciences
CSTL
|
71 M | $ 21.01 | -2.73 % | $ 609 M | USA |
 |
Fulgent Genetics
FLGT
|
192 M | $ 19.15 | -1.79 % | $ 589 M | USA |
 |
Aspira Women's Health
AWH
|
3.3 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
8.99 M | - | -61.36 % | $ 2.46 M | USA |
 |
Guardant Health
GH
|
349 M | $ 125.61 | -5.6 % | $ 15.7 B | USA |
 |
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | USA |
 |
Interpace Biosciences
IDXG
|
14.6 M | $ 1.67 | -6.7 % | $ 7.39 M | USA |
 |
Illumina
ILMN
|
1.47 B | $ 162.32 | -3.42 % | $ 25.2 B | USA |
 |
CareDx, Inc
CDNA
|
45.5 M | $ 22.25 | -3.76 % | $ 1.19 B | USA |
 |
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
ICON Public Limited Company
ICLR
|
6.08 B | $ 149.45 | -2.19 % | $ 11.7 B |  Irlanda |
 |
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | USA |
 |
Lantheus Holdings
LNTH
|
600 M | $ 100.98 | -1.79 % | $ 6.82 B | USA |
 |
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
361 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | USA |
 |
Natera
NTRA
|
158 M | $ 215.31 | -3.06 % | $ 29.4 B | USA |
 |
Pacific Biosciences of California
PACB
|
114 M | $ 1.45 | -11.04 % | $ 435 M | USA |
 |
Exact Sciences Corporation
EXAS
|
984 M | - | - | $ 19.8 B | USA |
 |
Myriad Genetics
MYGN
|
248 M | $ 4.57 | -2.56 % | $ 423 M | USA |
 |
Personalis
PSNL
|
53.9 M | $ 10.75 | -11.16 % | $ 959 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
9.78 B | $ 26.11 | 0.46 % | $ 24.8 B |  Niderland |
 |
Senseonics Holdings
SENS
|
19.5 M | $ 6.67 | -4.85 % | $ 278 M | USA |
 |
QIAGEN N.V.
QGEN
|
801 M | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
2.7 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
4.81 M | $ 2.12 | -1.17 % | $ 4.87 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
9.94 B | $ 265.15 | 1.6 % | $ 22.1 B | USA |
 |
Twist Bioscience Corporation
TWST
|
186 M | $ 69.22 | -6.37 % | $ 4.14 B | USA |
 |
Trinity Biotech plc
TRIB
|
40.1 M | $ 0.67 | -2.43 % | $ 241 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
81 K | - | -34.28 % | $ 263 K |  Israel |
 |
Waters Corporation
WAT
|
363 M | $ 365.36 | -2.95 % | $ 21.8 B | USA |
 |
Neogen Corporation
NEOG
|
473 M | $ 8.9 | -2.41 % | $ 1.93 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
7.37 B | $ 200.29 | 2.13 % | $ 22.2 B | USA |